3B Blackbio Dx Limited (BOM:532067)

India · Delayed Price · Currency is INR

1,463.50

+54.10 (3.84%)

At close: Sep 25, 2026

Market Cap	12.10B +1.1%
Revenue (ttm)	1.53B +54.3%
Net Income	555.29M +13.0%
EPS	65.19 +13.9%
Shares Out	8.58M
PE Ratio	21.62
Forward PE	n/a
Dividend	5.00 (0.34%)
Ex-Dividend Date	Sep 22, 2026

Volume	1,529
Open	1,409.75
Previous Close	1,409.40
Day's Range	1,383.80 - 1,475.00
52-Week Range	1,083.50 - 1,750.00
Beta	0.43
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About 3B Blackbio Dx

3B Blackbio Dx Limited manufactures and sells molecular diagnostic kits in India. The company designs, develops, manufactures and commercializes qPCR assays, rapid diagnostic tests, NGS-based diagnostic kits, digital PCR assays, and nucleic acid extraction solutions for reliable testing of patient samples, as well as offers oncology and hematology, antimicrobial resistance, infectious diseases, human genetics, extraction, and rapid antigen kits under the TRUPCR, TRUNGS, and TRURAPID brand names; and technical support and training services. 3B B... [Read more]

Industry Agricultural Chemicals

Founded 1972

Employees 86

Stock Exchange Bombay Stock Exchange

Ticker Symbol 532067

Full Company Profile

Financial Performance

In fiscal year 2026, 3B Blackbio Dx's revenue was 1.42 billion, an increase of 47.11% compared to the previous year's 964.69 million. Earnings were 599.30 million, an increase of 25.66%.

Financial Statements